A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 17, 2026 - P1/2 | N=343 | Recruiting | Sponsor: Antares Therapeutics, Inc | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2028 ➔ Oct 2029
Enrollment open • First-in-human • Monotherapy • Platinum resistant • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • HER-2
|